OptMed all set for $24 million IPO. Here’s what you need to know

This article was originally published on Alpha Street

As IPO activity picks up momentum after a lull, technology and healthcare companies are dominating the scene as usual. The upcoming initial public offering of medical device maker OptMed Inc. is one of the closely followed events of the year.

ipo news

OptMed is planning to raise about $24 million through an initial public offering, as per a regulatory submission made by the company. It has applied to list the stock on the Nasdaq Capital Market under the symbol OMED. However, the management is yet to reveal the number of shares being offered and the offer price.

Read management/analysts’ comments on quarterly reports

EF Hutton is the underwriter for the offering. The company intends to use the net proceeds from the offering for product development, marketing activities, and repayment of debt. A part of the amount will be used for general corporate and working capital purposes.

ipo news

Surgical Adhesives

OptMed, a clinical-stage medical device company, is mainly engaged in the development of topical skin protectant products and surgical adhesives, with a focus on the treatment of patients with external and internal wounds. BondEase, one of its lead products, got FDA approval a few years ago. Since then, the company has upgraded the product constantly and scaled manufacturing. Due to the changes, it is required to submit a new clearance application with regulators, which is expected to be done a few months after the IPO.

Everything you need to know about Ivanhoe Electric’s upcoming IPO

Besides BondEase, OptiMed is also developing TearRepair Liquid Skin Protectant, which is a topical protectant for fragile skin.

Founded in 2007, OptMed is headquartered in New York and is headed by chief executive officer Dr. Ervin Braun. Being part of a rapidly emerging segment of the healthcare industry, OptMed should be able to strengthen its foothold in the market. It is estimated that the global market for surgical sealants and adhesives would reach $2.8 billion by 2025. However, the company will have to compete with established players who enjoy an edge due to their better resources and experience.

Key Metrics

In fiscal 2021, OptMed incurred a net loss of $4.38 million, compared to a loss of $3.38 million in the prior year. The bottom line was negatively impacted by a 13% increase in operating expenses to $2.84 million. The company is yet to generate revenues because it has not commercially launched any product so far. To a large extent, Its growth prospects would depend on obtaining regulatory approval for the products.

The post OptMed all set for $24 million IPO. Here’s what you need to know first appeared on AlphaStreet.